Table 3.

Associations between time-varying statin and NSAID use and the risk of esophageal adenocarcinoma

Medication	Persons	Cases	Unadjusted HR (95% CI)	Age & Sex- Adjusted HR (95% CI)	Model 1c HR (95% CI)	Model 2 HR (95% CI)
All study population	395	45
Statin	143a	11	0.71 (0.32, 1.61)	0.63 (0.28–1.42)	0.59 (0.26, 1.33)	0.68 (0.30, 1.54) d
NSAID	284b	23	0.68 (0.38, 1.23)	0.57 (0.32–1.01)	0.58 (0.32, 1.02)	0.62 (0.34, 1.10) e
High grade dysplasia at baseline	69	30
Statin	25a	6	0.44 (0.16, 1.20)	0.35 (0.12- 1.07)	0.31 (0.11, 0.86)	0.41 (0.13, 1.26) d
NSAID	43b	12	0.44 (0.20, 0.96)	0.36 (0.16–0.80)	0.37 (0.17, 0.83)	0.46 (0.19, 1.09) e

^aEver used statins at baseline or over follow-up

^bEver used NSAIDs at baseline or over follow-up

^cAdjusted sex, age (continuous linear), and pack-years smoked (continuous linear)

^dAdjusted sex, age (continuous linear), pack-years smoked (continuous linear), and use of NSAIDs (yes/no) over follow-up

^eAdjusted sex, age (continuous linear), pack-years smoked (continuous linear), and use of statins (yes/no) over-follow-up